{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:21:26Z","timestamp":1791055286148,"version":"4.1.0"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>We present the case of a 66-year-old woman who developed weakness, nausea, and vomiting accompanied by markedly elevated creatine kinase levels after first treatment with an increased dose of tirzepatide. Laboratory findings were consistent with rhabdomyolysis and normalized within 4\u00a0days following discontinuation of tirzepatide and initiation of supportive intravenous fluid therapy. The temporal relationship strongly suggests tirzepatide as a likely trigger. Off-label use, particularly for weight loss, should be avoided and approached with caution. To the best of our knowledge, this is the first reported case of rhabdomyolysis following the initial administration of tirzepatide.<\/jats:p>","DOI":"10.3389\/fphar.2025.1660785","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:33:23Z","timestamp":1755668003000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Rhabdomyolysis following initiation of tirzepatide"],"prefix":"10.3389","volume":"16","author":[{"given":"Jonas Michael","family":"Bodanowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Mattes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha","family":"Loebermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fritzsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e50227","DOI":"10.7759\/cureus.50227","article-title":"Rhabdomyolysis associated with semaglutide therapy: a case report","volume":"15","author":"Billings","year":"2023","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","first-page":"101015","DOI":"10.1016\/j.disamonth.2020.101015","article-title":"Rhabdomyolysis","volume":"66","author":"Cabral","year":"2020","journal-title":"Dis. Mon."},{"key":"B3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1515\/CCLM.2010.151","article-title":"Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features","volume":"48","author":"Cervellin","year":"2010","journal-title":"Clin. Chem. Lab. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/01.md.0000188565.48918.41","article-title":"Rhabdomyolysis: an evaluation of 475 hospitalized patients","volume":"84","author":"Melli","year":"2005","journal-title":"Med. Baltim."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1111\/bcp.15757","article-title":"Rhabdomyolysis and statins: a pharmacovigilance comparative study between statins","volume":"89","author":"Montastruc","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1007\/s00125-023-05956-x","article-title":"Incretin hormones and type 2 diabetes","volume":"66","author":"Nauck","year":"2023","journal-title":"Diabetologia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/0002-9343(92)90740-3","article-title":"Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia","volume":"92","author":"Singhal","year":"1992","journal-title":"Am. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"005392","DOI":"10.12890\/2025_005392","article-title":"Rhabdomyolysis associated with the use of tirzepatide","volume":"12","author":"Sonavane","year":"2025","journal-title":"Eur. J. Case Rep. Intern Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes. Metab."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1660785\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:33:24Z","timestamp":1755668004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1660785\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":11,"alternative-id":["10.3389\/fphar.2025.1660785"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1660785","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"article-number":"1660785"}}